Board of Directors of Macter International, One of Pakistan’s Leading Pharmaceutical Company, has approved plan for acquiring Pharmaceutical company in Pakistan to increase its growth prospects.

The Board authorized the company to evaluate potential opportunities and conduct necessary feasibility studies, engage consultants, evaluators, and advisors as may be required from time to time. The Board of the company has authorized the management to enter into non-binding discussions, negotiations, and arrangements and present the same to the Board for their final consideration.

Macter’s operations currently focus on Contract manufacturing and branded generic formulations. Macter is the largest contract manufacturer in Pakistan particularly for the multinational companies with one of the most advanced production facilities offering a wide range of dosage forms: Oral solids and liquids, Parenterals (ampules and vials), Topicals, Metered dose Inhalers, Ear and Eye drops. Dedicated facilities are available for Cephalosporins, Penicillins & Biologics.

Macter’s Sales revenue stood at Rs.5.5 Billion in 2020 marking an average Sales growth rate of 18% over last five years. With massiv gross margins of 36%. Company posted Operating Profit of Rs. 295 million.

The potential Acquisition is expected to add value to the company by creating synergies.

The following two tabs change content below.


Please enter your comment!
Please enter your name here